Fc Receptors: Critical regulators of antibody biology and therapy
| Dates: | 24 February 2015 |
|---|
| Times: | 15:30 - 17:00 |
|---|
| What is it: | Seminar |
|---|
| Organiser: | Faculty of Medical and Human Sciences |
|---|
| Who is it for: | University staff, Adults, Current University students |
|---|
| Speaker: | Prof. Mark Cragg |
|---|
|
Mark Cragg, Professor in Experimental Cancer Biology, University of Southhampton, is interested in all aspects of how therapeutics result in tumour regression and is focused onthree main types - antibodies, chemotherapy and kinase inhibitors with the aim of understanding how these therapeutics function to delete tumour cells and how they might be augmented. In particular, he is interested in how monocolonal antibodies interact with Fc gamma receptors to achieve their therapeutic activities. Over the last decade, he has investigated many different therapeutic reagents such as rituximab, bexxar, imatinib, gefitinib, cetuximab and tarceva and has been involved in the development of next generation reagents such as ofatumumab and obinutuzumab.
Speaker
Prof. Mark Cragg
Role: Professor in Experimental Cancer Biology
Organisation: University of Southampton
Travel and Contact Information
Find event
Holt Majory Seminar Room
Patterson Building
Wilmslow Road
Manchester
